MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: IPSEN Group
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society - Ipsen, shared data from the company’s growing Rare Diseases Therapeutic Area, with the publication of eight abstracts in the Journal of the Endocrine Society.  - Endocrine.org / IPSEN.com
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2020/06/08 - Ipsen, shared data from the company’s growing Rare Diseases Therapeutic Area, with the publication of eight abstracts in the Journal of the Endocrine Society. - Endocrine.org / IPSEN.com. Euronext: IPN; ADR: IPSEY

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression;
• The Natural History Study (NHS) is the first protocol-specified, longitudinal evaluation of FOP disease progression.

The data include a first-of-its kind study titled,“A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes,” highlighting one-year data on the natural progression of FOP and the impact of heterotopic ossification (HO) on patients’ physical functioning over time.1 Ipsen and its partners also shared several studies detailing findings from health economics and outcomes research on the management of acromegaly.

FOP is an ultra-rare, severely disabling genetic bone disease that affects approximately 1.36 per million individuals worldwide.2,3 FOP is characterized by formation of bone in soft and connective tissues, known as heterotopic ossification (HO).4 Sporadic episodes of painful soft tissue swelling called ‘flare-ups’ can precede HO.4 HO is permanent, cumulative and severely impacts physical function over time with most patients’ movement becoming extremely limited, often confining them to a wheelchair by their twenties.4

The prospective Natural History Study (NHS) of FOP is the first global, multicenter, longitudinal study designed to measure disease progression over three years.1 Participant selection was representative of the FOP community worldwide and includes 114 patients with FOP who harbor a documented ACVR1 mutation, of those 99 (55 male / 44 female; mean age of group: 17.4 years) had both baseline and 12-month assessments and were included in the analysis. Ninety-three of the 99 participants had evaluable whole-body computed tomography and were included in the HO analysis.1

The analysis showed that over the course of 12 months, 40% (37/93) of participants had new HO.1 Of the NHS participants with new HO, 65% (24/37) reported at least one flare-up (mean rate of 2.3 flare-ups/year).1 60% (56/93) of NHS participants did not experience new HO over 12 months.1 Of those participants, 43% (24/56) reported at least one flare-up (mean rate of 1.8 flare-ups/year).1 CAJIS and FOP-PFQ were not sufficiently sensitive to assess FOP disease progression over 12 months.

“The results show that evaluating HO may be a viable way to measure disease progression and potential treatment effect,” said study co-investigator and co-author, Mona Al Mukaddam, M.D., MS of the Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania. “By examining the natural course of FOP, we hope to better understand the physical burden of HO as well as the link between flare-ups and disease progression.”

Additional abstracts published in the Journal of the Endocrine Society included data on the management of patients living with FOP or acromegaly.5-11

“Our research reinforces Ipsen’s commitment to actively listen to and work with patients, physicians, nurses, patient association groups, and other key stakeholders to best address the complexity and challenges of living with rare diseases such as FOP or acromegaly,” said Jim Roach, M.D., Senior Vice President and Global Head, Rare Diseases Therapeutic Area at Ipsen. “These diseases impact the quality of life both for patients and their caregivers and often place economic and societal burdens due to absences from work and high healthcare costs. Enhancing our understanding of these diseases will hopefully allow us to develop solutions that meaningfully impact patients.”

Contacts:
Kelly Blaney - Vice President, Global Communications
P: +44(0)79 0340 2275 - E: kelly.blaney[.]ipsen.com.

Eugenia Litz - Vice President, Investor Relations
P: +44(0)17 5362 7721 - E: eugenia.litz[.]ipsen.com.

Myriam Koutchinsky - Investor Relations Manager
P: +33(0)1 58 33 51 04 - E: myriam.koutchinsky[.]ipsen.com.

References

1. Al Mukaddam M et al. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Journal of the Endocrine Society.
2. Lilijesthrom M & Bogard B. The Global Known FOP Population. Presented at the FOP Drug Development Forum. Boston, MA; 2016.
3. Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet Journal of Rare Diseases. 2017; 12:123.
4. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations, IFOPA. Accessed: May 2020.
5. Kou S et al. Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities. Journal of the Endocrine Society.
6. Singh S et al. Surgical Management of Bilateral Hip Fracture in a Patient with Fibrodysplasia Ossificans Progressiva Treated with Palovarotene. Journal of the Endocrine Society.
7. Yuen K et al. Acromegaly Significantly Impacts Employees’ Health Benefit Costs and Increases Work Absenteeism. Journal of the Endocrine Society.
8. Ribeiro-Oliveira A et al. Healthcare Services Utilization and Costs Associated with the Management of Patients Living with acromegaly. Journal of the Endocrine Society.
9. Whittington M et al. Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population. Journal of the Endocrine Society.
10. Olsson D et al. Long-Acting SSA Treatment Patterns in Sweden From 2005 to 2017: A Nationwide Study. Journal of the Endocrine Society.
11. Adelman D et al. An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe. Journal of the Endocrine Society.
12. Brue F et al. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet Journal of Rare Diseases. 2016;11:135 52
13. Somatuline Autogel 60mg SmPC. Accessed: May 2020.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Christian Marcoux - IPSEN.com 
+33(0)1 58 33 67 94 christian.marcoux[.]ipsen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IPSEN Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IPSEN Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  VR CORPORATENEXT





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)